Skip to content

The proteomics of rhabdomyosarcoma in children and adolescents: Identification of a protein biomarkers

The proteomics of rhabdomyosarcoma in children and adolescents: Identification of a protein biomarkers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024156
Enrollment
Unknown
Registered
2019-06-28
Start date
2019-06-30
Completion date
Unknown
Last updated
2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhabdomyosarcoma

Interventions

Gold Standard:Diagnostic criteria for rhabdomyosarcoma: children with pathological tissue diagnosed as rhabdomyosarcoma
spectrum,&#32

Sponsors

Beijing Children's Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: (1) Clear pathological diagnosis; (2) Patients who have not started treatment before the first diagnosis of RMS; (3) Aged less than 18 years; (4) Meet the ethical requirements for the diagnosis and treatment of childhood cancer and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Heavier condition; (2) Combine other types of tumors; (3) Renal insufficiency; (4) accompanied by other diseases that seriously affect the state of the body.

Design outcomes

Primary

MeasureTime frame
proteomics;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactXiaoli Ma

Beijing Children's Hospital, Capital Medical University

mxl1123@vip.sina.com+86 010 59617612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026